Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New glasses tested to see how Kids' eyes focus

NCT ID NCT04700111

Knowledge-focused Sponsor: SightGlass Vision, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the eye focuses (lag of accommodation) when children with nearsightedness wear special DOT pattern spectacle lenses compared to regular glasses. About 30 kids aged 6 to 18 will have their vision measured at distance and close-up with each lens type. The goal is to understand if these lenses change how the eye focuses, which could help improve future myopia treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DOT Pattern Spectacle Lens
What this could lead to
If successful, this could help refine lens designs to slow myopia progression in children.
What could go wrong
This is a small, early-stage study (30 participants) measuring only a temporary eye response, not long-term vision outcomes. Results may not translate to real-world myopia control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Feb 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

A person is eligible for inclusion in the study if he/she: 1. Age 6-18 years of age, with a maximum of 6 of the first 25 completed participants being older than 14 years of age. 2. Is able to read (or be read to), understand and sign the assent document if under 17 years old or is able to read, understand and sign the consent document if aged 17 or 18 years. 3. Is under 17 years old and is accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document. 4. Should be emmetropic by non-cycloplegic auto-refraction, which means both refractive meridians should be within +1.00D and -1.00D. 5. Is willing and able to follow instructions. A person will be excluded from the study if he/she: 1. Is participating in any concurrent clinical or research study. 2. Have a history of myopia control treatment in the past year. 3. Has amblyopia in either eye or known to have any other binocular vision disorder, such as accommodative insufficiency. 4. Has any known active ocular disease and/or infection. 5. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable. Examples include diabetes mellitus, hyperthyroidism. 6. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable. Examples include Atropine eye drops. 7. Has undergone strabismus surgery, refractive error surgery or intraocular surgery. 8. Is a child of a member of the study team.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia, myopia progression, lag of accommodation, hyperopic retinal blur, reduction in contrast are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia, myopia progression, lag of accommodation, hyperopic retinal blur, reduction in contrast

Contacts and locations

Locations

  • Centre for Ocular Research and Education

    Waterloo, Ontario, N2L 3G1, Canada